{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:06:16Z","timestamp":1789729576621,"version":"4.0.1"},"reference-count":231,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer evolves within tissue ecosystems in which innate immune surveillance and tumor-promoting inflammation jointly shape disease progression and therapeutic response. Innate receptors detect cellular stress, altered-self ligands, damaged-cell products and tumor-derived nucleic acids, thereby initiating cytotoxicity, phagocytosis, antigen presentation and adaptive immune priming. However, tumors can redirect these mechanisms through suppressive cytokines, metabolic competition, hypoxia and dysregulated chemokine networks, promoting immune exclusion, metastasis and treatment resistance. This Review examines innate recognition, immunoediting and innate\u2013adaptive crosstalk. We discuss the heterogeneity, dysfunction and therapeutic targeting of dendritic cells, macrophages, natural killer cells, neutrophils, myeloid-derived suppressor cells, innate lymphoid cells and other tissue-resident populations. We also evaluate Toll-like receptor, cGAS\u2013STING, RIG-I\u2013MAVS, inflammasome and complement pathways as therapeutically actionable but potentially tumor-promoting signaling systems. Finally, we consider how innate adjuvants, antigen selection, delivery technologies and rational combinations can improve therapeutic cancer vaccines. Emerging clinical studies demonstrate feasibility, but inconsistent efficacy and treatment-associated toxicity emphasize the need for biomarker-guided patient selection, spatially restricted delivery and mechanism-based sequencing. Clinical translation will depend on biomarker-guided patient selection, localized delivery and treatment sequencing that preserves antimicrobial defense and tissue homeostasis.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1941235","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:52:39Z","timestamp":1789728759000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinghan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dequan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01039-5","article-title":"Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity","volume":"6","author":"Han","year":"2025","journal-title":"Nat Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00760-x","article-title":"An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy","volume":"5","author":"Chen","year":"2024","journal-title":"Nat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaz2738","article-title":"NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists","volume":"5","author":"Nicolai","year":"2020","journal-title":"Sci Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005518","article-title":"Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections","volume":"11","author":"van Puffelen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1038\/s41467-022-34041-x","article-title":"DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response","volume":"13","author":"Baldwin","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150735","article-title":"VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment","volume":"6","author":"Zhang","year":"2021","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","article-title":"Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models","volume":"21","author":"Keklikoglou","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06464-z","article-title":"Non-cell-autonomous cancer progression from chromosomal instability","volume":"620","author":"Li","year":"2023","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","article-title":"Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma","volume":"15","author":"Ghosh","year":"2023","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","article-title":"Interleukin-1\u03b1 release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity","volume":"42","author":"H\u00e4nggi","year":"2024","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05880-5","article-title":"STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma","volume":"616","author":"Hu","year":"2023","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.cd-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","article-title":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial","volume":"42","author":"Davar","year":"2024","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.immuni.2020.06.002","article-title":"Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells","volume":"53","author":"Bourdely","year":"2020","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","article-title":"Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer","volume":"55","author":"Nixon","year":"2022","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1126\/science.adg1955","article-title":"Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape","volume":"383","author":"Sharma","year":"2024","journal-title":"Sci (New York NY)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7(+) dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adq8843","article-title":"Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4(+) T cell response","volume":"9","author":"Chudnovskiy","year":"2024","journal-title":"Sci Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1038\/s41467-022-34428-w","article-title":"Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s43018-025-00929-y","article-title":"Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade","volume":"6","author":"Catena","year":"2025","journal-title":"Nat Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: The MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101377","article-title":"Lymph node and tumor-associated PD-L1(+) macrophages antagonize dendritic cell vaccines by suppressing CD8(+) T cells","volume":"5","author":"Sprooten","year":"2024","journal-title":"Cell Rep Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1038\/s41467-025-60769-3","article-title":"Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7\/8 prodrugs in mice","volume":"16","author":"Yin","year":"2025","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03651-8","article-title":"Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells","volume":"595","author":"Casanova-Acebes","year":"2021","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk3981","article-title":"Timing and location dictate monocyte fate and their transition to tumor-associated macrophages","volume":"9","author":"Dunsmore","year":"2024","journal-title":"Sci Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Sci (New York NY)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240957","article-title":"Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis","volume":"222","author":"Ray","year":"2025","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8(+) T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1168","article-title":"Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted","volume":"16","author":"Governa","year":"2024","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41467-022-28076-3","article-title":"Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells","volume":"13","author":"Borriello","year":"2022","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1038\/s41467-021-27308-2","article-title":"Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101307","article-title":"Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I\/II first-in-human MATINS trial","volume":"4","author":"Rannikko","year":"2023","journal-title":"Cell Rep Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet (London England)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3018","article-title":"The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Sci (New York NY)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","article-title":"In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases","volume":"41","author":"Kerzel","year":"2023","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01884-z","article-title":"Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping","volume":"25","author":"Netskar","year":"2024","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet (London England)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf6493","article-title":"Deterministic reprogramming of neutrophils within tumors","volume":"383","author":"Ng","year":"2024","journal-title":"Sci (New York NY)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326070","article-title":"Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment","volume":"72","author":"Wang","year":"2023","journal-title":"Gut"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon-stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add5204","article-title":"Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis","volume":"8","author":"Gong","year":"2023","journal-title":"Sci Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2394-6","article-title":"DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","article-title":"Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation","volume":"41","author":"Mousset","year":"2023","journal-title":"Cancer Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.ccell.2025.06.007","article-title":"Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps","volume":"43","author":"He","year":"2025","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13046-024-03240-3","article-title":"Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models","volume":"43","author":"Horn","year":"2024","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B110","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-024-02710-x","article-title":"Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment","volume":"131","author":"Masui","year":"2024","journal-title":"Br J Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01410-2","article-title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","volume":"42","author":"Armstrong","year":"2024","journal-title":"Invest New Drugs"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-1020","article-title":"A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c09318","article-title":"Localized degradation of neutrophil extracellular traps by photoregulated enzyme delivery for cancer immunotherapy and metastasis suppression","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.04.013","article-title":"Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases","volume":"357","author":"Wang","year":"2023","journal-title":"J Control Release"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu5915","article-title":"Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils","volume":"11","author":"Heath","year":"2025","journal-title":"Sci Adv"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01180-z","article-title":"Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy","volume":"8","author":"Kumbhojkar","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c02013","article-title":"Neutrophil-mediated delivery of nanocrystal drugs via photoinduced inflammation enhances cancer therapy","volume":"17","author":"Su","year":"2023","journal-title":"ACS Nano"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411307","article-title":"Controlled inflammation drives neutrophil-mediated precision drug delivery in heterogeneous tumors","volume":"12","author":"Guo","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2101","article-title":"Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens","volume":"7","author":"Monteith","year":"2021","journal-title":"Sci Adv"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101380","article-title":"Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors","volume":"5","author":"Pettinella","year":"2024","journal-title":"Cell Rep Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201803","article-title":"Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice","volume":"218","author":"Veglia","year":"2021","journal-title":"J Exp Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Sci (New York NY)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-1921","article-title":"Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"15424","DOI":"10.1038\/s41598-017-14970-0","article-title":"Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration","volume":"7","author":"Markowitz","year":"2017","journal-title":"Sci Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J Exp Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0447","article-title":"Impact of surgery-induced myeloid-derived suppressor cells and the NOX2\/ROS axis on postoperative survival in human pancreatic cancer","volume":"4","author":"Grauer Wiktorin","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9","article-title":"Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal","volume":"21","author":"Baumann","year":"2020","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci Adv"},{"key":"B132","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.can-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0061-3","article-title":"c-Rel is a myeloid checkpoint for cancer immunotherapy","volume":"1","author":"Li","year":"2020","journal-title":"Nat Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","article-title":"LXR\/ApoE activation restricts innate immune suppression in cancer","volume":"172","author":"Tavazoie","year":"2018","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501853","article-title":"Yeast-derived particulate \u03b2-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer","volume":"196","author":"Albeituni","year":"2016","journal-title":"J Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2495","article-title":"Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma","volume":"29","author":"Tobin","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3560","article-title":"Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice","volume":"20","author":"Qin","year":"2014","journal-title":"Nat Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1784","article-title":"Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody","volume":"23","author":"Dominguez","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad088","article-title":"A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma","volume":"5","author":"Ghosh","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1396-8","article-title":"Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer","volume":"62","author":"Iclozan","year":"2013","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01213-2","article-title":"Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine Malignancies","volume":"23","author":"Kansler","year":"2022","journal-title":"Nat Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2015-4","article-title":"ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity","volume":"579","author":"Moral","year":"2020","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/s41467-021-22764-2","article-title":"PPAR\u03b3 drives IL-33-dependent ILC2 pro-tumoral functions","volume":"12","author":"Ercolano","year":"2021","journal-title":"Nat Commun"},{"key":"B147","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2023.12.015","article-title":"Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"B148","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1016\/j.cell.2021.07.029","article-title":"Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer","volume":"184","author":"Goc","year":"2021","journal-title":"Cell"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08426-5","article-title":"IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer","volume":"638","author":"Amisaki","year":"2025","journal-title":"Nature"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100961","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological Malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"11666","DOI":"10.1038\/s41467-025-66801-w","article-title":"Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial","volume":"16","author":"Iinuma","year":"2025","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/s41467-019-10676-1","article-title":"IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization","volume":"10","author":"Eissmann","year":"2019","journal-title":"Nat Commun"},{"key":"B157","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41467-017-00327-8","article-title":"Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B","volume":"8","author":"Wroblewski","year":"2017","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat Commun"},{"key":"B159","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41467-025-61324-w","article-title":"Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18","volume":"16","author":"Fan","year":"2025","journal-title":"Nat Commun"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03776-7","article-title":"Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial","volume":"31","author":"Wu","year":"2025","journal-title":"Nat Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb5943","article-title":"Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"key":"B164","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"key":"B165","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1016\/j.cell.2024.09.016","article-title":"Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis","volume":"187","author":"Dalla","year":"2024","journal-title":"Cell"},{"key":"B166","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2025.01.008","article-title":"Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases","volume":"43","author":"Rodriguez-Baena","year":"2025","journal-title":"Cancer Cell"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1172\/jci157937","article-title":"In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis","volume":"133","author":"Liu","year":"2023","journal-title":"J Clin Invest"},{"key":"B168","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat Commun"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00727","article-title":"Randomized, open-label, phase III study of Tilsotolimod in combination with Ipilimumab versus Ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE-301)","volume":"43","author":"Diab","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1505174","article-title":"Toll like receptor 7 expressed by Malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells","volume":"8","author":"Dajon","year":"2019","journal-title":"Oncoimmunology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Sci (New York NY)"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-022-01251-z","article-title":"STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity","volume":"21","author":"Dane","year":"2022","journal-title":"Nat Mater"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313693120","article-title":"ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer","volume":"120","author":"Wang","year":"2023","journal-title":"PNAS"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau8943","article-title":"RIG-I activation is critical for responsiveness to checkpoint blockade","volume":"4","author":"Heidegger","year":"2019","journal-title":"Sci Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190801","article-title":"Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses","volume":"216","author":"Jiang","year":"2019","journal-title":"J Exp Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c06225","article-title":"Nanoparticle retinoic acid-inducible gene I agonist for cancer immunotherapy","volume":"18","author":"Wang-Bishop","year":"2024","journal-title":"ACS Nano"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03191-8","article-title":"Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies","volume":"71","author":"Moreno","year":"2022","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009352","article-title":"Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma","volume":"13","author":"Eigentler","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc6998","article-title":"The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation","volume":"6","author":"Han","year":"2021","journal-title":"Sci Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1172\/jci133055","article-title":"A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy","volume":"130","author":"Theivanthiran","year":"2020","journal-title":"J Clin Invest"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.immuni.2021.07.002","article-title":"\u03b2(2)-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression","volume":"54","author":"Hofbauer","year":"2021","journal-title":"Immunity"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B186","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/jco.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1172\/jci90962","article-title":"The role of the complement system in cancer","volume":"127","author":"Afshar-Kharghan","year":"2017","journal-title":"J Clin Invest"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0891","article-title":"Tumor cells hijack macrophage-produced complement C1q to promote tumor growth","volume":"7","author":"Roumenina","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201654","article-title":"Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression","volume":"189","author":"Corrales","year":"2012","journal-title":"J Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10353-6","article-title":"mRNA vaccines engage unconventional pathways in CD8(+) T cell priming","volume":"654","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"B194","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet (London England)"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat Commun"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: Phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08758-w","article-title":"STING agonist-based ER-targeting molecules boost antigen cross-presentation","volume":"641","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.02.056","article-title":"RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade","volume":"41","author":"Heidegger","year":"2019","journal-title":"EBioMedicine"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102922","article-title":"New chimeric TLR7\/NOD2 agonist is a potent adjuvant to induce mucosal immune responses","volume":"58","author":"Gutjahr","year":"2020","journal-title":"EBioMedicine"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01249-4","article-title":"Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines","volume":"22","author":"Ostroumov","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.12079","article-title":"Regulated cell death-amplified sonodynamic anti-tumor immune nanotherapeutics","volume":"2","author":"Zhou","year":"2024","journal-title":"BMEMat"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.12076","article-title":"Recent advances in biomimetic aggregation-induced emission photosensitizers for photodynamic therapy and immunotherapy","volume":"2","author":"Guo","year":"2024","journal-title":"BMEMat"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.70003","article-title":"Designing next-generation immune cell therapies with nanomaterials","volume":"3","author":"Chen","year":"2025","journal-title":"BMEMat"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.12077","article-title":"Metal coordination-driven assembly of stimulator of interferon genes-activating nanoparticles for tumor chemo-immunotherapy","volume":"2","author":"Zhang","year":"2024","journal-title":"BMEMat"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000691","article-title":"Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate na\u00efve and memory NY-ESO-1-specific CD8(+) T cells","volume":"8","author":"Masterman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B217","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1038\/s41467-025-61299-8","article-title":"An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: A phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat Cancer"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69294-3","article-title":"The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: A single-arm, phase II study","volume":"17","author":"Lee","year":"2026","journal-title":"Nat Commun"},{"key":"B221","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1038\/s41467-024-48931-9","article-title":"PIKfyve, expressed by CD11c-positive cells, controls tumor immunity","volume":"15","author":"Choi","year":"2024","journal-title":"Nat Commun"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114875","article-title":"Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy","volume":"43","author":"Keshari","year":"2024","journal-title":"Cell Rep"},{"key":"B223","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat Commun"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B225","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.annonc.2026.04.010","article-title":"IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma","volume":"37","author":"Hassel","year":"2026","journal-title":"Ann Oncol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1159\/000533650","article-title":"PHOCUS: A phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2024","journal-title":"Liver Cancer"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30517-x","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108516","article-title":"ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors","volume":"203","author":"Liu","year":"2025","journal-title":"Lung Cancer"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:52:41Z","timestamp":1789728761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":231,"alternative-id":["10.3389\/fimmu.2026.1941235"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1941235","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1941235"}}